Some studies with longer treatment durations have shown improved diastolic function with SGLT2 inhibitor treatment in patients with T2D, possibly due to reduced left ventricular myocardial mass, whereas others have not [39–42]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.